Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7NUG

Influenza A/California/07/2009(H1N1) endonuclease in complex with orientin

Summary for 7NUG
Entry DOI10.2210/pdb7nug/pdb
DescriptorPolymerase acidic protein,Polymerase acidic protein, MANGANESE (II) ION, MAGNESIUM ION, ... (9 entities in total)
Functional Keywordsendonuclease, protein-ligand complex, rna polymerase, flavonoids, viral protein
Biological sourceInfluenza A virus (A/California/07/2009(H1N1))
More
Total number of polymer chains1
Total formula weight22741.84
Authors
Radilova, K.,Brynda, J. (deposition date: 2021-03-12, release date: 2021-07-28, Last modification date: 2024-01-31)
Primary citationReiberger, R.,Radilova, K.,Kral, M.,Zima, V.,Majer, P.,Brynda, J.,Dracinsky, M.,Konvalinka, J.,Kozisek, M.,Machara, A.
Synthesis and In Vitro Evaluation of C-7 and C-8 Luteolin Derivatives as Influenza Endonuclease Inhibitors.
Int J Mol Sci, 22:-, 2021
Cited by
PubMed Abstract: The part of the influenza polymerase PA subunit featuring endonuclease activity is a target for anti-influenza therapies, including the FDA-approved drug Xofluza. A general feature of endonuclease inhibitors is their ability to chelate Mg or Mn ions located in the enzyme's catalytic site. Previously, we screened a panel of flavonoids for PA inhibition and found luteolin and its C-glucoside orientin to be potent inhibitors. Through structural analysis, we identified the presence of a 3',4'-dihydroxyphenyl moiety as a crucial feature for sub-micromolar inhibitory activity. Here, we report results from a subsequent investigation exploring structural changes at the C-7 and C-8 positions of luteolin. Experimental IC values were determined by AlphaScreen technology. The most potent inhibitors were C-8 derivatives with inhibitory potencies comparable to that of luteolin. Bio-isosteric replacement of the C-7 hydroxyl moiety of luteolin led to a series of compounds with one-order-of-magnitude-lower inhibitory potencies. Using X-ray crystallography, we solved structures of the wild-type PA-N-terminal domain and its I38T mutant in complex with orientin at 1.9 Å and 2.2 Å resolution, respectively.
PubMed: 34299354
DOI: 10.3390/ijms22147735
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.9 Å)
Structure validation

237735

數據於2025-06-18公開中

PDB statisticsPDBj update infoContact PDBjnumon